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Risk score for predicting death, myocardial infarction, and stroke in
patients with stable angina, based on a large randomised trial cohort
of patients
Tim C Clayton, Jacobus Lubsen, Stuart J Pocock, Zoltán Vokó, Bridget-Anne Kirwan, Keith A A Fox, Philip A
Poole-Wilson, on behalf of the ACTION investigators
Abstract
Objective To derive a risk score for the combination of death
from all causes, myocardial infarction, and disabling stroke in
patients with stable symptomatic angina who require treatment
for angina and have preserved left ventricular function.
Design Multivariate Cox regression analysis of data from a
large multicentre trial.
Setting Outpatient cardiology clinics in western Europe, Israel,
Canada, Australia, and New Zealand.
Participants 7311 patients with all required data available.
Main outcome measure Death from any cause or myocardial
infarction or disabling stroke during a mean follow-up of 4.9
years.
Results 1063 patients either died from any cause or sustained
myocardial infarction or disabling stroke. The five year risk of
this composite ranged from 4% for patients in the lowest tenth
of risk to 35% for patients in the highest tenth. The risk score
combines 16 routinely available clinical variables (in order of
decreasing contribution): age, left ventricular ejection fraction,
smoking, white blood cell count, diabetes, casual blood glucose
concentration, creatinine concentration, previous stroke, at least
one angina attack a week, coronary angiographic findings (if
available), lipid lowering treatment, QT interval, systolic blood
pressure ≥ 155 mm Hg, number of drugs used for angina,
previous myocardial infarction, and sex. Fitting the same model
separately to all cause death, myocardial infarction, and stroke
gave similar results. The risk score did not seem to predict the
nature of the event (death in 39%, myocardial infarction in 46%,
and disabling stroke in 15%) or the incidence of angiography
or revascularisation, which occurred in 29% of patients.
Conclusion This risk score is an objective aid in deciding on
further management of patients with stable angina with the aim
of reducing serious outcome events. The score can also be used
in planning future trials.
Introduction
While patients with stable angina have low mortality,1–3 the risk of
myocardial infarction and stroke remains substantial and quality
of life is often reduced by symptoms. In managing these patients,
physicians face complex choices concerning secondary preven-
tion, drugs to treat angina, and indications for coronary angiog-
raphy and revascularisation.4
Because the absolute benefit of any treatment to improve
prognosis depends on the risk of disease events, such risks
require consideration, especially if treatment has possible
complications. Scoring cardiovascular risk was first developed in
Framingham.5 Many studies have followed, mainly for scoring
risk in the primary prevention of cardiovascular diseases.6 No
similar risk score is available for patients with angina.
Development of a risk score requires a large comprehensive
database on patients followed for several years. A potential
source is data from large randomised clinical trials.7 We used data
from the ACTION trial (a coronary disease trial investigating
outcome with nifedipine GITS), which followed 7665 patients
with stable symptomatic angina for a mean of 4.9 years,3 to
develop a score for predicting the combined risk of death from
any cause, myocardial infarction, and stroke.
Methods
In the ACTION trial, eligible patients had stable symptomatic
angina requiring treatment and either previous myocardial
infarction or proved angiographic coronary artery disease.
Patients without a previous myocardial infarction or coronary
angiography could participate only if there was a positive result
on an exercise or perfusion test.3 8 Key exclusions were ejection
fraction below 40%, clinically significant heart failure, major car-
diovascular event or intervention within the past three months,
planned coronary angiography or intervention, and known
intolerance to dihydropyridines.
Patients were randomly assigned long acting nifedipine GITS
or placebo and were seen regularly at outpatient clinics and con-
tacted by telephone thereafter. The mean follow-up until death
or the end of the study was 4.9 years.
Individual baseline data available included demographics,
medical history, cardiovascular risk factors, current symptoms of
angina and functional status, current treatments, past use of cal-
cium channel blockers, results of non-fasting laboratory tests, left
ventricular ejection fraction mostly measured by echocardiogra-
phy, standard 12 lead electrocardiography findings, routine cuff
blood pressure, pulse rate, and the results of previous angiogra-
phy if available (baseline angiography was not mandated).
We fitted multivariate Cox proportional hazard models for
the outcome time to death, myocardial infarction, or disabling
stroke as adjudicated by the critical events committee,3 8 using
patients who had no missing values for the predictor variables.
Examples of applying the risk score can be found on bmj.com
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We represented binary or categorical variables by indicator vari-
ables coded 0 or 1. Quantitative variables were investigated for
non-linearity, and cut off values were determined when
appropriate. For instance, for age, 60 years was the cut off value
whereby any age < 60 contributed the same risk. Always
entering age, sex, and previous myocardial infarction, we added
other variables to the final model using P < 0.01 as inclusion cri-
terion. We ignored nifedipine as it had no effect on this
combined end point (hazard ratio 1.01, 95% confidence interval
0.90 to 1.14).3
We expressed each variable’s strength of predictive contribu-
tion by its z score (the model coefficient divided by its standard
error) and quantified each variable’s predictive power as a hazard
ratio with 95% confidence interval. To assess the predictive
power separately for each of death from any cause, myocardial
infarction, and disabling stroke, we refitted the final model using
the same covariates for each of the three outcomes concerned.
For each patient, we calculated a risk score by multiplying
each coefficient in the final model by 10, then by the patient’s
variable value, and then summed up the results. From the distri-
bution of the risk scores, we formed equal sized tenths of
increasing risk. Model calibration was evaluated by comparing
actual and predicted outcomes in each tenth of risk, the actual
outcome being the five year Kaplan-Meier probability estimate
and the expected probability being calculated from the final
model. The internal validity of the final model was assessed by
the bootstrap resampling technique.9 For each of 100 bootstrap
samples the model was refitted and tested on the original sample
to obtain an estimate of predictive accuracy corrected for bias.
This revealed no overoptimism in the final model’s predictive
discrimination. We calculated the rate of coronary intervention
including coronary angiography, percutaneous coronary inter-
vention, or bypass surgery in the tenths of the risk score to study
the relation between the predicted risk of major cardiovascular
events and the use of coronary interventions.
Results
Table 1 shows the 16 variables, with their z scores and Cox
regression coefficients, that were in the final model as derived for
7311 patients (95%) with complete information. In all 1063
patients died or sustained myocardial infarction or disabling
stroke. Table 1 also shows how we derived the risk score (see
bmj.com for examples). Table 2 presents the corresponding haz-
ard ratios for the composite of death, myocardial infarction, and
stroke. Age was the strongest predictor (hazard ratio 1.73 for
each decade of age > 60). Male sex (hazard ratio 1.17) was of
borderline significance (P = 0.06) but was retained for complete-
ness. Diabetes and stroke were the strongest predictors from
clinical history. Patients with known three or more vessel disease
had raised risk. The final model also includes several standard
risk factors, such as current smoking, and the laboratory results
for white blood cell count, creatinine, and glucose. The latter
contributed most to prediction in those without diabetes and was
not predictive in those with diabetes treated with insulin. Other
predictors included were left ventricular ejection fraction, a pro-
longed QT interval, use of lipid lowering drugs, and the number
of drugs used for angina (including past use of calcium blockers).
Table 2 also presents hazard ratios for the individual events of
death, myocardial infarction, and disabling stroke with the same
variables as for the combined end point. Patterns of risk factors
were broadly similar, though risk of stroke was more strongly
linked to raised blood pressure but unrelated to white cell count,
angiographic data, previous myocardial infarction, and sex.
Figure 1 shows the distribution of the risk score (multiplied
by ten) based on the coefficients and definitions given in table 1,
and also its association with the probability of death, myocardial
infarction, and disabling stroke within five years. Figure 2 shows
good agreement between the observed and expected propor-
tions of patients having this composite event within five years.
Among patients with risk scores in the top and bottom tenths,
the probability of an event was 35% and 4%, respectively. The
Kaplan-Meier plots for each tenth showed that event rates were
essentially constant over six years’ follow-up.
Table 3 shows the number of patients who sustained the
composite of death, myocardial infarction, and disabling stroke
by tenth of risk with the corresponding event rates. First events
comprised 417 (39%) deaths, 490 (46%) myocardial infarctions,
and 156 (15%) disabling strokes, and the distribution of first
event did not vary substantially by tenth of risk. Table 3 also
shows the distribution by tenth of risk of the 2147 patients (29%)
who had a coronary angiogram or coronary revascularisation
procedure during follow-up. There was no relation between
these intervention rates and the risk of death, myocardial infarc-
tion, and stroke.
Discussion
Our study confirms that most patients with stable symptomatic
coronary disease have a relatively good prognosis.1 2 Our main
finding is the large variation in risk of death, myocardial
infarction, and disabling stroke between patients that can be
determined from an easily calculated risk score using standard
clinical information. Others have previously studied predictors
of clinical outcome in patients with stable angina10 but on fewer
patients followed for a shorter period.
That patients in the top 10% of risk had ten times the risk of
patients in the bottom 10% of risk is clinically relevant. Coronary
revascularisation prolongs survival only in high risk patients.4
Hence, risk stratification using our score helps to identify
patients with stable angina for whom elective revascularisation
might improve prognosis. Risk stratification aids decisions on
secondary preventive medical management, especially when
limited resources exist for coronary angiography and revascu-
larisation. Patients at high risk of serious clinical events can be
given priority so as to avoid such events while they are waiting
for an invasive procedure.
We found no relation between the use of procedures related
to treatment of angina and risk of death, myocardial infarction,
and stroke, which suggests that events related to plaque rupture
(cardiovascular death, myocardial infarction) have a different
pathology and different risk factors from worsening angina
caused by progression of coronary artery disease. This implies
that our risk score contains no information regarding whether a
patient will need a coronary angiogram or revascularisation pro-
cedure because of worsening angina. Hence, risk stratification
has no bearing on prescribing drug treatment for angina to
avoid the need for coronary revascularisation.
We deliberately focused prediction on important life events:
death, unequivocal myocardial infarction, and stroke that is disa-
bling. Contrary to current recommendations,11 our definition of
myocardial infarction did not include patients with chest pain
and raised troponin concentrations. The definition of stroke
excluded events without lasting disability.3 We included 206 non-
cardiovascular deaths (19% of all deaths), which may reduce the
predictive power of risk factors particularly related to cardiovas-
cular outcomes, but none the less makes the model more useful
for clinical application.
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Many of the risk factors we identified are not surprising. Age,
ejection fraction, smoking, and diabetes are all known predictors
from other studies. Statins have been shown to reduce mortality,
myocardial infarction, and stroke in several settings.12 The link
between white blood cell count and coronary disease risk is
established.13 Other markers of inflammation such as C reactive
protein were not measured. Raised serum creatinine concentra-
tion is linked to adverse cardiovascular outcome in several popu-
lations, including people with hypertension,14 myocardial
infarction,15 and acute coronary syndrome.16 The extent of angi-
ographic coronary disease is a well established risk factor.4 That
patients who never had coronary angiography had a slightly
higher risk than patients who had known zero to two vessel dis-
ease seems surprising: one likely explanation is that the former
includes some patients with extensive, albeit undocumented,
coronary disease. One could confine the analysis to patients with
angiographic information, but this would limit the clinical
relevance as many patients with angina never have coronary
angiography.
The possibility exists that design issues in the ACTION trial
could influence our prognostic models. For instance, patients on
a calcium channel blocker could not participate in the trial,
though 22% of patients had used a calcium channel blocker in
the past. Past use of a calcium channel blocker was a significant
predictor in the present analysis and we have retained such past
use in the model by incorporating it in the number of drugs used
for angina. The present risk score is limited to patients with pre-
served left ventricular function who did not have any condition,
other than coronary artery disease, that limits life expectancy.
Our risk score may also be useful in planning future clinical
trials in similar patients by, for instance, enabling them to
exclude low risk patients.
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Table 1 Predictors of death, myocardial infarction (MI), or disabling stroke for 7311 participants in the ACTION trial (Cox proportional hazards analysis).
Figures are numbers (percentages) unless stated otherwise
Death, MI or stroke
(n=1063)*
No death, MI or stroke
(n=6248)* z score† Coefficient Contribution to risk score
Mean (SD) age (years) 66.5 (9.5) 63.0 (9.2) 10.77 0.55 0 when age ≤60 years or add per 10 years >60 years
Mean (SD) ejection fraction (%) 46.7 (6.6) 48.6 (6.3) 6.47 0.17 0 when ≥60% or add per 5% <60%
Smoking‡:
Never 260 (24) 1784 (29) — — 0
Ex-smoker 560 (53) 3417 (55) 1.54 0.12 Add if applicable
Current 243 (23) 1047 (17) 6.12 0.60 Add if applicable
Mean (SD) white blood cells (109/l) 7.4 (2.5) 7.0 (1.8) 6.07 0.068 0 when ≤5 109/l or add per 109/l >5
Diabetes‡:
No diabetes 848 (80) 5393 (86) — — 0
Non-ID diabetes 167 (16) 727 (12) 1.06 0.13 Add if applicable
ID diabetes 48 (5) 128 (2) 5.61 0.85 Add if applicable
Mean (SD) glucose, no diabetes (mg/dl)§ 103 (26) 99 (20) 4.68 0.072 0 when ≤100 mg/dl or add per 10 mg/dl >100 mg/dl
Mean (SD) glucose, non-ID diabetes (mg/dl)§ 189 (79) 168 (65) 3.36 0.032 0 when ≤100 mg/dl or add per 10 mg/dl >100 mg/dl
Mean (SD) creatinine (mg/dl)¶ 1.14 (0.25) 1.08 (0.21) 4.27 0.078 0 when ≤1.15 mg/dl or add per 0.1 mg/dl >1.15 mg/dl
Previous stroke** 50 (5) 116 (2) 3.59 0.53 Add if yes
Angina attack ≥1/week** 364 (34) 1750 (28) 3.42 0.22 Add if applicable
Previous angiography‡:
Never done 350 (33) 1842 (29) 1.50 0.11 Add if applicable
0-2 vessel disease†† 421 (40) 3069 (49) — — Add 0 if applicable
≥3 vessel disease 292 (27) 1337 (21) 3.23 0.25 Add if applicable
No lipid lowering therapy 406 (38) 1950 (31) 3.20 0.21 Add if not on therapy
QT interval (12 lead ECG) ≥430 msec** 238 (22) 1096 (18) 3.05 0.23 Add if applicable
Systolic blood pressure ≥155 mm Hg** 275 (26) 1097 (18) 2.84 0.21 Add if applicable
No of drugs for angina:
0 8 (1) 53 (1) — —
1 268 (25) 1953 (31) 2.76 0.13 Add once for each drug used
2 626 (59) 3487 (56)
3 161 (15) 755 (12)
Previous MI** 597 (56) 3118 (50) 2.16 0.14 Add if yes
Male** 863 (81) 4944 (79) 1.87 0.16 Add if male
ID=insulin dependent.
*Model is based on 7311 patients with values for all variables in model, of whom 1063 had the combined event of death, MI, or disabling stroke.
†Coefficient divided by its SE. Larger values indicate more highly significant risk factor: z scores of 1.96, 2.58, 3.29, and 3.89 correspond to P=0.05, P=0.01, P=0.001, and P=0.0001,
respectively.
‡Categorical variable represented by two indicator variables in model, reference category shown.
§×0.0555 to convert values to mmol/l.
¶×88.4 to convert values to mol/l.
**Binary variable, reference category not shown.
††No of major coronary arteries with clinically significant lesions for all coronary angiograms performed. Left main disease was counted as two vessel disease.
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Table 2 Predictors of death, myocardial infarction (MI), and disabling stroke for 7311 participants in the ACTION trial (Cox proportional hazards analysis).
Figures are hazard ratios (95% confidence intervals)
Death, MI, or stroke (n=1063) Death (n=569) MI (n=495) Stroke (n=170)
Age per 10 years >60 1.73 (1.57 to 1.92) 2.30 (2.01 to 2.64) 1.45 (1.25 to 1.69) 1.75 (1.37 to 2.24)
Ejection fraction per 5% <60 1.19 (1.13 to 1.25) 1.26 (1.17 to 1.35) 1.14 (1.06 to 1.23) 1.24 (1.09 to 1.41)
Smoking*:
Never 1.00 1.00 1.00 1.00
Ex-smoker 1.13 (0.97 to 1.32) 1.19 (0.96 to 1.48) 0.99 (0.79 to 1.24) 1.42 (0.95 to 2.13)
Current 1.82 (1.50 to 2.20) 2.20 (1.69 to 2.85) 1.39 (1.05 to 1.84) 2.44 (1.49 to 3.99)
White blood cells per 109/l >5 1.07 (1.05 to 1.09) 1.09 (1.07 to 1.12) 1.05 (1.01 to 1.10) 1.00 (0.92 to 1.09)
Diabetes*:
No diabetes 1.00 1.00 1.00 1.00
Non-ID diabetes 1.14 (0.90 to 1.44) 0.93 (0.66 to 1.32) 1.14 (0.81 to 1.60) 1.75 (1.06 to 2.90)
ID diabetes 2.33 (1.74 to 3.14) 3.44 (2.40 to 4.94) 2.62 (1.75 to 3.93) 0.56 (0.14 to 2.29)
Glucose per 10 mg/dl >100† (no diabetes) 1.08 (1.04 to 1.11) 1.10 (1.06 to 1.14) 1.05 (1.00 to 1.10) 1.07 (0.98 to 1.15)
Glucose per 10 mg/dl >100† (non-ID diabetes) 1.03 (1.01 to 1.05) 1.04 (1.01 to 1.07) 1.03 (1.00 to 1.06) 1.03 (0.99 to 1.07)
Creatinine per 0.1 mg/dl >1.15‡ 1.08 (1.04 to 1.12) 1.09 (1.04 to 1.14) 1.08 (1.02 to 1.14) 1.06 (0.97 to 1.16)
Previous stroke§ 1.70 (1.27 to 2.28) 1.74 (1.19 to 2.54) 1.50 (0.95 to 2.36) 4.28 (2.60 to 7.06)
Angina attack ≥1/week§ 1.25 (1.10 to 1.42) 1.27 (1.07 to 1.51) 1.21 (1.00 to 1.46) 1.16 (0.84 to 1.61)
Previous angiography*:
Never done 1.12 (0.97 to 1.30) 1.16 (0.95 to 1.41) 1.20 (0.96 to 1.49) 1.10 (0.77 to 1.58)
0-2 vessel disease¶ 1.00 1.00 1.00 1.00
≥3 vessel disease 1.28 (1.10 to 1.50) 1.14 (0.92 to 1.41) 1.50 (1.21 to 1.87) 1.06 (0.72 to 1.57)
No lipid lowering therapy§ 1.23 (1.08 to 1.40) 1.33 (1.12 to 1.58) 1.10 (0.91 to 1.33) 1.09 (0.79 to 1.51)
QT interval (12-lead ECG) ≥430 msec§ 1.26 (1.08 to 1.45) 1.52 (1.26 to 1.84) 1.08 (0.87 to 1.35) 1.42 (1.00 to 2.01)
Systolic blood pressure ≥155 mm Hg§ 1.23 (1.07 to 1.42) 1.18 (0.98 to 1.43) 1.09 (0.88 to 1.35) 1.69 (1.22 to 2.36)
For each additional drug for angina 1.14 (1.04 to 1.25) 1.09 (0.96 to 1.24) 1.20 (1.05 to 1.38) 1.21 (0.96 to 1.54)
Previous MI§ 1.15 (1.01 to 1.30) 1.10 (0.92 to 1.30) 1.16 (0.96 to 1.39) 1.01 (0.74 to 1.38)
Male§ 1.17 (0.99 to 1.39) 1.21 (0.96 to 1.52) 1.24 (0.97 to 1.59) 0.88 (0.59 to 1.30)
ID=insulin dependent.
*Categorical variable represented by two indicator variables in model, reference category shown.
†×0.0555 to convert values to mmol/l.
‡×88.4 to convert values to mol/l.
§Binary variable, reference category not shown
¶No of major coronary arteries with clinically significant lesions for all coronary angiograms performed. Left main disease was counted as two vessel disease.
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Table 3 Occurrence of death, myocardial infarction (MI), or disabling stroke and rate of coronary interventions by tenth of risk
Tenth of risk for death, MI,
or stroke*
No of deaths, MIs, or strokes
(No/100 person years)
First event (% of total death, MI, or stroke)
Any intervention† (No/100 person years)Death (%) MI (%) Stroke (%)
1st 31 (0.86) 5 (16) 21 (67) 5 (16) 188 (5.92)
2nd 43 (1.18) 9 (21) 25 (58) 9 (21) 210 (6.74)
3rd 64 (1.79) 23 (36) 37 (58) 4 (6) 238 (8.04)
4th 77 (2.18) 28 (36) 41 (53) 8 (10) 241 (8.22)
5th 72 (1.98) 30 (42) 32 (44) 10 (14) 208 (6.63)
6th 90 (2.56) 29 (32) 49 (54) 12 (13) 227 (7.70)
7th 101 (2.86) 42 (42) 44 (44) 15 (15) 205 (6.66)
8th 143 (4.20) 63 (44) 61 (43) 19 (13) 211 (7.08)
9th 169 (5.04) 65 (38) 70 (41) 34 (20) 214 (7.27)
10th 273 (8.93) 123 (45) 110 (40) 40 (15) 205 (7.32)
Total (n=7311) 1063 (3.05) 417 (39) 490 (46) 156 (15) 2147 (7.14)
*Tenths 1-9 consist of 731 patients each, last 10th consists of 732 patients.
†Coronary angiography, percutaneous coronary intervention, or bypass surgery.
What is already known on this topic
Many factors are known to affect the risk of death,
myocardial infarction, or stroke in patients with stable
symptomatic coronary disease (angina pectoris)
There is no method available to assess a patient’s overall
risk based on routine clinical information
What this study adds
A new score uses 16 clinical variables to quantify the
combined risk of death from any cause, myocardial
infarction, and disabling stroke
Patients with risk scores in the highest tenth have 10 times
the risk of patients with scores in the lowest tenth
The use of invasive procedures such as coronary
angiography or revascularisation undertaken to relieve
symptoms of angina was not related to the composite risk
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